Publications
May 12, 2016
BIOLOGICAL MARKERS FOR IDENTIFYING IBRUTINIB RESISTANCE IN PATIENTS HAVING MANTLE CELL LYMPHOMA AND METHODS OF USING THE SAME
Disclosed herein are methods of predicting a likelihood of responsiveness to treatment with ibrutinib in a patient having mantle cell lymphoma and methods of treating a patient having mantle cell…
April 1, 2016
Leveraging transcriptomic and genomic data to better select models for preclinical oncology therapeutic development to identify cell lines most similar to patient tumors
Cancer cell lines represent the front line of new compound testing, and results from these experiments often decide which compounds go on for further testing. Genomic context plays a critical…
February 1, 2016
Leveraging public genomic data to accelerate oncology therapeutic development in pancreatic cancer.
Pancreatic cancer has an estimated survival rate of only 5-6% (Siegel et al. 2015). The difficulty in early detection methods compounded by clinical trial failures precipitates the need for innovative…
December 3, 2015
Serum Proteomic Analysis of Multiple Myeloma Subjects Treated with Daratumumab Monotherapy
Daratumumab (DARA) is a human IgG1κ monoclonal antibody that binds with high affinity to a unique epitope on CD38. DARA monotherapy has shown promising activity in relapsed and/or refractory multiple…
November 24, 2015
Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition
Glatiramer acetate (Copaxone®; GA) is a non-biological complex drug for multiple sclerosis. GA modulated thousands of genes in genome-wide expression studies conducted in THP-1 cells and mouse splenocytes. Comparing GA…
Journal: Journal of Neuroimmunology
November 6, 2015
Accelerating pancreatic cancer drug screening by leveraging genomics to select better in vitro models.
Cell lines used for pre-clinical testing of oncology compounds are not always chosen based on how well they models patient tumors. Instead they are often chosen based on availability and…
September 23, 2015
Leveraging existing data sets to generate new insights into Alzheimer’s disease biology in specific patient subsets
To generate new insights into the biology of Alzheimer’s Disease (AD), we developed methods to combine and reuse a wide variety of existing data sets in new ways. We first…
Journal: Scientific Reports
August 1, 2015
Improving pancreatic cancer drug discovery by leveraging genomics to select better in vitro models
Currently, pancreatic cancer has an estimated 5-year survival rate of only 5-6%. The projection that pancreatic cancer will be the second leading cause of cancer related death by 2020 compounded…
June 25, 2015
Glatiramoids
Glatiramoids are non-biologic complex drugs (NBCDs) comprising four naturally occurring amino acids in a complex copolymeric mixture. The first and most thoroughly studied glatiramoid, glatiramer acetate (Copaxone®, Teva Pharmaceutical Industries,…
May 22, 2015
Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids
Sub Title Goes Here
Journal: Scientific Reports
Page 8 of 9
